APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Spinal Muscular Atrophy (SMA)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for Spinal Muscular Atrophy (SMA) Market Analysis and Forecast 2026-2032

Report ID 173986520229 December 2025198 pages

Choose your research edition.

Industry ResearchDrugs for Spinal Muscular Atrophy (SMA) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Spinal Muscular Atrophy (SMA) Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Drugs for Spinal Muscular Atrophy (SMA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Spinal Muscular Atrophy (SMA) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Spinal Muscular Atrophy (SMA) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Drugs for Spinal Muscular Atrophy (SMA) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Drugs for Spinal Muscular Atrophy (SMA) include Novartis, Ionis Pharmaceuticals, Genentech and Biogen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Drugs for Spinal Muscular Atrophy (SMA), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Spinal Muscular Atrophy (SMA), also provides the sales of main regions and countries. Of the upcoming market potential for Drugs for Spinal Muscular Atrophy (SMA), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Spinal Muscular Atrophy (SMA) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Spinal Muscular Atrophy (SMA) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Spinal Muscular Atrophy (SMA) sales, projected growth trends, production technology, application and end-user industry.

Drugs for Spinal Muscular Atrophy (SMA) Segment by Company

Novartis

Ionis Pharmaceuticals

Genentech

Biogen

Drugs for Spinal Muscular Atrophy (SMA) Segment by Type

Oral Drugs

Injections

Drugs for Spinal Muscular Atrophy (SMA) Segment by Application

Hospital

Clinic

Other

Drugs for Spinal Muscular Atrophy (SMA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Spinal Muscular Atrophy (SMA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Spinal Muscular Atrophy (SMA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Spinal Muscular Atrophy (SMA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Drugs for Spinal Muscular Atrophy (SMA) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Drugs for Spinal Muscular Atrophy (SMA) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Spinal Muscular Atrophy (SMA) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Drugs Major Manufacturers Table 3. Injections Major Manufacturers Table 4. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Other Major Manufacturers Table 8. Drugs for Spinal Muscular Atrophy (SMA) Industry Trends Table 9. Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers Table 10. Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges Table 11. Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints Table 12. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021-2026) Table 16. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2027-2032) Table 17. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021-2026) & (K Units) Table 19. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2027-2032) & (K Units) Table 20. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021-2026) Table 21. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2027-2032) Table 22. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021-2026) Table 26. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Drugs for Spinal Muscular Atrophy (SMA) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Drugs for Spinal Muscular Atrophy (SMA) Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers, Product Type & Application Table 30. Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Drugs for Spinal Muscular Atrophy (SMA) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021-2026) Table 37. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2027-2032) Table 38. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 40. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 41. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021-2026) Table 42. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2027-2032) Table 43. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021-2026) & (US$/Unit) Table 44. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2027-2032) & (US$/Unit) Table 45. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021-2026) Table 49. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2027-2032) Table 50. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 52. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 53. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021-2026) Table 54. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2027-2032) Table 55. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2027-2032) & (US$/Unit) Table 57. Novartis Company Information Table 58. Novartis Business Overview Table 59. Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 61. Novartis Recent Development Table 62. Ionis Pharmaceuticals Company Information Table 63. Ionis Pharmaceuticals Business Overview Table 64. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 66. Ionis Pharmaceuticals Recent Development Table 67. Genentech Company Information Table 68. Genentech Business Overview Table 69. Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 71. Genentech Recent Development Table 72. Biogen Company Information Table 73. Biogen Business Overview Table 74. Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 76. Biogen Recent Development Table 77. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 80. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 81. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2021-2026) & (US$/Unit) Table 82. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2027-2032) & (US$/Unit) Table 83. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2026) & (US$ Million) Table 84. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027-2032) & (US$ Million) Table 85. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 86. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 87. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2021-2026) & (US$/Unit) Table 88. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2027-2032) & (US$/Unit) Table 89. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 91. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 92. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 93. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 94. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 95. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2021-2026) & (US$/Unit) Table 96. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2027-2032) & (US$/Unit) Table 97. United States Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 98. Canada Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 99. Mexico Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 100. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2026) & (US$ Million) Table 101. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027-2032) & (US$ Million) Table 102. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 103. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 104. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2021-2026) & (US$/Unit) Table 105. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2027-2032) & (US$/Unit) Table 106. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2026) & (US$ Million) Table 107. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027-2032) & (US$ Million) Table 108. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 109. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 110. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2021-2026) & (US$/Unit) Table 111. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2027-2032) & (US$/Unit) Table 112. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 114. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 115. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 116. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 117. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 118. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2021-2026) & (US$/Unit) Table 119. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2027-2032) & (US$/Unit) Table 120. Germany Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 121. France Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 122. U.K. Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 123. Italy Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 124. Russia Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 125. Spain Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 126. Netherlands Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 127. Switzerland Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 128. Sweden Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 129. Poland Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 130. China Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2026) & (US$ Million) Table 131. China Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027-2032) & (US$ Million) Table 132. China Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 133. China Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 134. China Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2021-2026) & (US$/Unit) Table 135. China Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2027-2032) & (US$/Unit) Table 136. China Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2026) & (US$ Million) Table 137. China Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027-2032) & (US$ Million) Table 138. China Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 139. China Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 140. China Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2021-2026) & (US$/Unit) Table 141. China Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2027-2032) & (US$/Unit) Table 142. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2026) & (US$ Million) Table 143. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027-2032) & (US$ Million) Table 144. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 145. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 146. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2021-2026) & (US$/Unit) Table 147. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2027-2032) & (US$/Unit) Table 148. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2026) & (US$ Million) Table 149. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 151. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 152. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2021-2026) & (US$/Unit) Table 153. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2027-2032) & (US$/Unit) Table 154. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 156. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 157. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 158. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 159. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 160. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2021-2026) & (US$/Unit) Table 161. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2027-2032) & (US$/Unit) Table 162. Japan Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 163. South Korea Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 164. India Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 165. Australia Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 166. Taiwan Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 167. Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 168. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2026) & (US$ Million) Table 169. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027-2032) & (US$ Million) Table 170. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 171. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 172. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2021-2026) & (US$/Unit) Table 173. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Type (2027-2032) & (US$/Unit) Table 174. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2026) & (US$ Million) Table 175. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027-2032) & (US$ Million) Table 176. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 177. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 178. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2021-2026) & (US$/Unit) Table 179. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Application (2027-2032) & (US$/Unit) Table 180. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 182. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 183. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 184. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 185. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 186. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2021-2026) & (US$/Unit) Table 187. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Country (2027-2032) & (US$/Unit) Table 188. Brazil Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 189. Argentina Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 190. Chile Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 191. Colombia Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 192. Peru Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 193. Saudi Arabia Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 194. Israel Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 195. UAE Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 196. Turkey Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 197. Iran Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 198. Egypt Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Table 199. Key Raw Materials Table 200. Raw Materials Key Suppliers Table 201. Drugs for Spinal Muscular Atrophy (SMA) Distributors List Table 202. Drugs for Spinal Muscular Atrophy (SMA) Customers List Table 203. Research Programs/Design for This Report Table 204. Authors List of This Report Table 205. Secondary Sources Table 206. Primary Sources List of Figures Figure 1. Drugs for Spinal Muscular Atrophy (SMA) Image Figure 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Drugs Image Figure 5. Injections Image Figure 6. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Figure 13. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021-2032) Figure 16. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (2021-2032) & (K Units) Figure 17. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Drugs for Spinal Muscular Atrophy (SMA) Sales YoY (2021-2032) & (K Units) Figure 20. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales YoY (2021-2032) & (K Units) Figure 21. China Drugs for Spinal Muscular Atrophy (SMA) Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Drugs for Spinal Muscular Atrophy (SMA) Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales YoY (2021-2032) & (K Units) Figure 24. Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021-2032) Figure 30. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021-2032) Figure 33. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021-2032) Figure 36. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021-2032) Figure 39. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Type (2021-2032) Figure 40. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Type (2021-2032) Figure 41. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Application (2021-2032) Figure 42. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Application (2021-2032) Figure 43. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country (2021-2032) Figure 44. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country (2021-2032) Figure 45. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Type (2021-2032) Figure 46. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Type (2021-2032) Figure 47. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Application (2021-2032) Figure 48. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Application (2021-2032) Figure 49. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country (2021-2032) Figure 50. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country (2021-2032) Figure 51. China Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Type (2021-2032) Figure 52. China Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Type (2021-2032) Figure 53. China Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Application (2021-2032) Figure 54. China Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Application (2021-2032) Figure 55. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Type (2021-2032) Figure 56. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Type (2021-2032) Figure 57. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Application (2021-2032) Figure 58. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Application (2021-2032) Figure 59. Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country (2021-2032) Figure 60. Asia Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country (2021-2032) Figure 61. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Type (2021-2032) Figure 62. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Type (2021-2032) Figure 63. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Application (2021-2032) Figure 64. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Application (2021-2032) Figure 65. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country (2021-2032) Figure 66. SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Country (2021-2032) Figure 67. Drugs for Spinal Muscular Atrophy (SMA) Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Novartis
  • Ionis Pharmaceuticals
  • Genentech
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Spinal Muscular Atrophy (SMA) Market by Type
  3. 1.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Drugs
  5. 1.2.3 Injections
  6. 1.3 Drugs for Spinal Muscular Atrophy (SMA) Market by Application
  7. 1.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Drugs for Spinal Muscular Atrophy (SMA) Market Dynamics
  1. 2.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
  2. 2.2 Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers
  3. 2.3 Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges
  4. 2.4 Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region
  3. 3.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2021-2026)
  5. 3.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2027-2032)
  6. 3.2.4 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region
  9. 3.4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021-2026)
  11. 3.4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2027-2032)
  12. 3.4.4 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Manufacturers
  2. 4.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Manufacturers
  6. 4.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Drugs for Spinal Muscular Atrophy (SMA) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Drugs for Spinal Muscular Atrophy (SMA) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers, Product Type & Application
  13. 4.7 Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market CR5 and HHI
  16. 4.8.2 2025 Drugs for Spinal Muscular Atrophy (SMA) Tier 1, Tier 2, and Tier 3
5 Drugs for Spinal Muscular Atrophy (SMA) Market by Type
  1. 5.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type
  2. 5.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type
  6. 5.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type
6 Drugs for Spinal Muscular Atrophy (SMA) Market by Application
  1. 6.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application
  2. 6.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application
  6. 6.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Ionis Pharmaceuticals
  8. 7.2.1 Ionis Pharmaceuticals Company Information
  9. 7.2.2 Ionis Pharmaceuticals Business Overview
  10. 7.2.3 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  12. 7.2.5 Ionis Pharmaceuticals Recent Developments
  13. 7.3 Genentech
  14. 7.3.1 Genentech Company Information
  15. 7.3.2 Genentech Business Overview
  16. 7.3.3 Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  18. 7.3.5 Genentech Recent Developments
  19. 7.4 Biogen
  20. 7.4.1 Biogen Company Information
  21. 7.4.2 Biogen Business Overview
  22. 7.4.3 Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  24. 7.4.5 Biogen Recent Developments
8 North America
  1. 8.1 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Type
  2. 8.1.1 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2032)
  3. 8.1.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2032)
  4. 8.1.3 North America Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021-2032)
  5. 8.2 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Application
  6. 8.2.1 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2032)
  7. 8.2.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2032)
  8. 8.2.3 North America Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021-2032)
  9. 8.3 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  10. 8.3.1 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Drugs for Spinal Muscular Atrophy (SMA) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Type
  2. 9.1.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2032)
  4. 9.1.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021-2032)
  5. 9.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Application
  6. 9.2.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2032)
  8. 9.2.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021-2032)
  9. 9.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  10. 9.3.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Drugs for Spinal Muscular Atrophy (SMA) Market Size by Type
  2. 10.1.1 China Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2032)
  3. 10.1.2 China Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2032)
  4. 10.1.3 China Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021-2032)
  5. 10.2 China Drugs for Spinal Muscular Atrophy (SMA) Market Size by Application
  6. 10.2.1 China Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2032)
  7. 10.2.2 China Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2032)
  8. 10.2.3 China Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Spinal Muscular Atrophy (SMA) Market Size by Type
  2. 11.1.1 Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2032)
  4. 11.1.3 Asia Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021-2032)
  5. 11.2 Asia Drugs for Spinal Muscular Atrophy (SMA) Market Size by Application
  6. 11.2.1 Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2032)
  8. 11.2.3 Asia Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021-2032)
  9. 11.3 Asia Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  10. 11.3.1 Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Drugs for Spinal Muscular Atrophy (SMA) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Market Size by Type
  2. 12.1.1 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021-2032)
  5. 12.2 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Market Size by Application
  6. 12.2.1 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021-2032)
  9. 12.3 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country
  10. 12.3.1 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Drugs for Spinal Muscular Atrophy (SMA) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Drugs for Spinal Muscular Atrophy (SMA) Value Chain Analysis
  2. 13.1.1 Drugs for Spinal Muscular Atrophy (SMA) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process
  6. 13.2 Drugs for Spinal Muscular Atrophy (SMA) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Drugs for Spinal Muscular Atrophy (SMA) Distributors
  9. 13.2.3 Drugs for Spinal Muscular Atrophy (SMA) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst